13 April 2022
\n \n \n \nCongratulations to the amazing team of research nurses working in the Primary Care Clinical Trials Unit who have been shortlisted as finalists in the Oxford University Hospitals NHS Foundation Trust Staff Recognition Awards 2021.
\n \n\n \n \n4 April 2022
\n \n \n \n10,000 people have joined the PRINCIPLE Trial over the last two years and we want to say a big \u2018Thank You\u2019 to them all for their amazing contribution to testing treatments for COVID-19 in the community.
\n \n\n \n \n31 March 2022
\n \n \n \nThe world\u2019s largest study of community-based treatments for acute COVID-19 has reached a world-first, historic milestone: over twenty thousand participants from across the UK have now taken part in the PANORAMIC trial.
\n \n\n \n \n8 December 2021
\n \n \n \nResearchers from the University of Oxford have today started recruiting participants for a first-of-its-kind clinical trial to test novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 and those who are at higher risk of complications \u2013 partnering with the National Institute for Health Research (NIHR) and working with colleagues in several UK universities, and the NHS UK-wide.
\n \n\n \n \n5 July 2021
\n \n \n \nThe PRINCIPLE trial has been highly commended at the Health Data Research UK Awards for the way in which patient data is utilised so participants are contacted about the trial soon after receiving a positive test result.
\n \n\n \n \n23 June 2021
\n \n \n \nFrom today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world\u2019s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
\n \n\n \n \n20 May 2021
\n \n \n \nEach year, International Clinical Trials Day recognises the people who conduct clinical trials, giving our community a chance to say thank you for everything they do to improve public health. This year our trials unit staff are sharing what makes them proud to be part of Oxford\u2019s Primary Care Clinical Trials Unit.
\n \n\n \n \n12 April 2021
\n \n \n \nInhaled budesonide, a common corticosteroid, is the world's first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. As of today, the treatment is available in UK primary care on a case-by-case basis.
\n \n\n \n \n8 April 2021
\n \n \n \nCould the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
\n \n\n \n \n3 March 2021
\n \n \n \nFrom today, the UK\u2019s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
\n \n\n \n \n25 January 2021
\n \n \n \nUpdate from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
\n \n\n \n \n27 November 2020
\n \n \n \nIn Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
\n \n\n \n \n18 November 2020
\n \n \n \nTwo of the UK\u2019s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.
\n \n\n \n \n23 October 2020
\n \n \n \nThe importance of patient and public contributors is recognised as key to the success of the study.
\n \n\n \n \n21 October 2020
\n \n \n \nEurope\u2019s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
\n \n\n \n \n1 October 2020
\n \n \n \nMore than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
\n \n\n \n \n18 September 2020
\n \n \n \nProfessor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
\n \n\n \n \n7 July 2020
\n \n \n \nThere is no evidence to suggest a daily combination of probiotics reduces the need for antibiotics to treat acute infections in care home residents, finds a study led by Oxford University researchers published in JAMA.
\n \n\n \n \n26 May 2020
\n \n \n \n\n \n \n12 May 2020
\n \n \n \n\n \n \n